Michael Lauseker, Markus Pfirrmann, Verena S. Hoffmann and Joerg Hasford (2012) “Comment on ‘Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed’ Haematologica 2011;96(12):1779–82”, Haematologica. Pavia, Italy, 97(5), pp. e14-e15. doi: 10.3324/haematol.2011.061630.